Implant Sciences Adds Romanian Airports to its list of Customers, Achieves Sales to a Total of 70 Countries Worldwide

WILMINGTON, Mass., Aug. 11, 2015 /PRNewswire/ -- Implant Sciences Corporation (OTCQB: IMSC), a leading manufacturer of explosives trace detection (ETD) and drugs trace detection solutions for homeland security applications, today announced that its QS-B220 desktop explosives trace detector has been selected in a Romanian airport tender. With this sale, Implant Sciences' trace detectors have been sold to customers in 70 different countries around the world, amounting to a total of approximately 4,400 units.

"Implant Sciences has, in this year, doubled the number of units sold in its entire history of selling trace detectors," stated Dr. Darryl Jones, Implant Sciences' Vice President of Global Sales and Marketing. "This sale to Romania is another example of smaller EU country airports following market trends set by other, larger airports. We continue to capitalize on our tremendous sales momentum globally."

"Over the last several months, our QS-B220 has been recognized by some of the most high-profile airport security operators and ETD customers in the world, being selected in tenders across ten different EU countries," added Dr. Bill McGann, CEO of Implant Sciences. "We believe this is a clear sign that our recent momentum is being sustained, as these highly sophisticated customers look to Implant Sciences as the emerging leader in trace detection and to our technology as being the new standard in the market."

About the QS-B220 Desktop Explosives Trace Detector

The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.

About Implant Sciences

Implant Sciences is a leader in developing and manufacturing advanced detection capabilities to counter and eliminate the ever-evolving threats from explosives and drugs. The Company's team of dedicated trace detection experts has developed proprietary technologies used in its commercial products, thousands of which have been sold across 70 countries worldwide. The Company's ETDs have received approvals and certifications from several international regulatory agencies including the TSA in the U.S., ECAC in Europe, CAAC and the Ministry of Public Safety in China, Russia FSB, STAC in France, and the German Ministry of the Interior. It has also received the 2015 GSN Airport/Seaport/Border Security Award for "Best Security Checkpoint".  All Implant Sciences products are recognized as Qualified Anti-Terrorism Technologies by the Department of Homeland Security. For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Cautionary Note Regarding Forward-Looking Statements

This press release and any statements of employees, representatives and partners of Implant Sciences Corporation (the "Company") related thereto contain or may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995.  Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions.  Such statements are based on management's current expectations and are subject to significant risks and uncertainties (many of which are beyond the Company's control) that could cause the Company's actual results to differ materially from the forward-looking statements.  Such risks and uncertainties include, but are not limited to, the risks that there is no guaranty that the Transportation Security Administration (TSA) or any other U.S. or foreign government and law enforcement agencies or commercial consumers will purchase any of our explosives detection products or that any new products we may develop will be accepted by the TSA or by such other governments, agencies or consumers; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change, and our ability to generate revenue and profit will depend on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K.  In light of these risks and uncertainties, readers are cautioned that actual results may differ significantly from those described or anticipated in the forward-looking statements.  The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.

Contact:

Implant Sciences Corporation Company Contact: Robert Liscouski 978-752-1700 x 116  

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/implant-sciences-adds-romanian-airports-to-its-list-of-customers-achieves-sales-to-a-total-of-70-countries-worldwide-300126873.html

SOURCE Implant Sciences Corporation